Top Stories· August 17, 2026 at 09:00 a.m.
New Study Links Gut Bacteria Metabolite to Alzheimer's Progression
Key takeaways
- Imidazole propionate (ImP) is a gut bacteria metabolite linked to Alzheimer’s disease progression
- Higher levels of ImP correlate with worse cognitive performance and higher levels of Alzheimer's biomarkers
- The study suggests that ImP can compromise the blood-brain barrier and enter the brain, promoting changes related to amyloid beta and tau
Scientists have identified a gut bacteria metabolite, imidazole propionate (ImP), as a possible link between the microbiome and Alzheimer's disease. The study, published in Nature Communications, suggests that ImP can compromise the blood-brain barrier, enter the brain, and promote changes related to amyloid beta and tau, key players in Alzheimer’s disease. Higher levels of ImP were found to correlate with worse cognitive performance and higher levels of Alzheimer's biomarkers in a study of 1,196 cognitively healthy adults.
